Background
==========

The incidence of cervical cancer in the United States continues to decline, with an estimated 12,170 cases of invasive cancer to be diagnosed in 2012 \[[@B1]\]. Unfortunately, cervical cancer continues to be the leading cause of cancer mortality in women in developing countries, resulting in approximately 190,000 deaths per year \[[@B2]\]. While the prognosis for early-stage disease is excellent, with 5-year survival rates approaching 90% \[[@B3]\], the prognosis for locally advanced disease with pelvic sidewall or locoregional lymph node involvement is poor \[[@B4],[@B5]\]. This is also true for women with locally recurrent cancer, where poor prognostic factors include pelvic sidewall fixation, early recurrence after primary therapy, and tumor recurrence \>3 cm in greatest dimension \[[@B6]-[@B8]\].

The importance of achieving local control in patients with cervical cancer cannot be overemphasized, as more than half of recurrences after primary therapy are limited to the pelvis \[[@B9]\]. Furthermore, persistent pelvic disease may result in significant morbidity including pain, anorexia, vaginal bleeding, cachexia, and/or psychological problems \[[@B10]\], and approximately 60% of women who die of cervical cancer have local failure as the major cause of death \[[@B11]\]. Retrospective studies of radiation alone have shown a dose--response relationship for pelvic disease control in locally advanced cervical cancer; \[[@B12]\] however, the use of higher radiation doses to improve tumor control may result in significant morbidity, particularly when reirradiation is attempted in the salvage setting \[[@B13]\]. Intraoperative radiotherapy (IORT) has been used at our institution and at others to give a focally-targeted radiotherapy boost at the time of surgery to areas of close or positive surgical margins to maximize radiotherapy dose while minimizing irradiation of normal tissues \[[@B14]-[@B24]\]. Here we update a previous report with long-term outcomes from the largest single-institution series of women with locally advanced or recurrent cervical cancer treated with a combined modality approach that includes IORT.

Methods
=======

The Mayo Clinic Institutional Review Board (IRB) approved this study. We queried the prospectively-maintained IORT database for patients with cervical carcinoma treated with IORT at Mayo Clinic, Rochester, MN from 1980 to 2010. All patients were treated with a combined modality approach that included, at a minimum, surgery and IORT. Patients selected for this approach had either locally advanced primary cervix cancer with pelvic wall extension and/or extensive paraaortic (PA) lymph node (LN) involvement or locally recurrent cervix cancer within the pelvis and/or abdomen. In addition to having pathologically-confirmed disease, patients underwent a multidisciplinary evaluation that included a radiation oncologist and a gynecologic oncologist. In cases where chemotherapy was deemed appropriate, a medical oncologist was also involved in all decision making.

Details regarding the administration of IORT at Mayo Clinic have been described previously \[[@B25]\] and are summarized as follows. IORT is delivered in a dedicated operating suite. All patients in this study were treated using high-energy electrons (IOERT) from a linear accelerator. IOERT was delivered employing one of a series of custom-made Lucite collimating devices of various lengths, shapes, and diameters, selected to best encompass the at-risk field. The dose was prescribed to the 90% isodose level such that ≥90% of the prescription dose was delivered to the margin in question. Resection margins were graded based on the both the surgeon's subjective assessment and the frozen pathologic assessment prior to the delivery of IOERT as R0 (microscopically negative), R1 (microscopically positive), or R2 (grossly positive). Dose was selected based on the amount of residual disease and proximity of critical structures. Routine follow-up after IOERT consisted of pelvic examination every three months with surveillance imaging of the abdomen and pelvis every six months for two years. Follow-up thereafter consisted of physical examination with imaging annually or as indicated by symptoms.

Clinical data including patterns of failure, survival, and toxicity were recorded prospectively in the IORT database through patient visits or contact with local physicians. All endpoints were defined from the date of IOERT. Determination of disease progression was made based on radiographic and/or physical exam findings. Central control (CC) was defined as freedom from recurrence within the IOERT field. Locoregional control (LRC) was defined freedom from recurrence within the IOERT field as well as locoregional lymph nodes. Freedom from distant relapse (FFDR) was defined as freedom from relapse in sites outside the pelvis and paraaortic region. Toxicity was scored using the NCI Common Toxicity Criteria (CTCAE) v.4.

The Kaplan-Meier (KM) method was used to determine cause specific (CSS) and overall survival (OS). The cumulative incidence methodology was used to calculate rates of central relapse (CR), locoregional relapse (LRR) and distant relapse (DR). For patients with recurrent cervical cancer, the Log-Rank test was used to assess an array of variables for potential impact on clinical outcomes. These variables included tumor grade (low vs. high), history of previous radiotherapy (RT; yes vs. no), multiple previous recurrences (yes vs. no), time period during which IOERT occurred (1983--1996 vs. 1997--2010), time from initial diagnosis to recurrence treated with IOERT (≤6 months vs. \>6 months), tumor size prior to IOERT (\<3 cm vs. ≥3 cm), type of surgery performed in conjunction with IOERT (pelvic exenteration vs. less invasive surgery), surgical margin grade prior to delivery of IOERT (R0 vs. R1 vs. R2), pelvic sidewall involvement by tumor (yes vs. no), perioperative external beam radiotherapy +/− brachytherapy (EBRT +/− BT; yes vs. no), and perioperative chemotherapy (yes vs. no). Variables associated with outcomes by the Log-Rank test were then assessed using a multivariate Cox proportional hazard model controlled for patient age. These variables included tumor grade, time from initial diagnosis to recurrence treated with IOERT, history of previous RT, type of surgery performed in conjunction with IOERT, surgical margin grade, perioperative RT, and perioperative systemic therapy. In all cases, a *P* value of \<0.05 was considered significant. All statistical analysis was performed with JMP 8.0 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient and treatment characteristics
-------------------------------------

Of the 86 patients who met criteria for inclusion in this study, 73 (85%) had locally recurrent cervical cancer and 13 (15%) had locally advanced primary disease. The median age at IOERT was 48.6 years (range, 20.9-85.5 years). Most patients had squamous cell carcinoma histology (n = 68, 79%), and the majority of tumors were high-grade (n = 73, 85%). The median tumor size was 5.0 cm (range, 0.5-14.0 cm). Table [1](#T1){ref-type="table"} summarizes patient and tumor characteristics at the time of IOERT.

###### 

Patient and tumor characteristics at the time of recurrence treated with IOERT

  **Characteristic**                            **Value (%)**
  -------------------------------------------- ---------------
  Patients (n)                                       86
  Age (y)                                              
   Median                                           48.6
   Range                                          20.9-85.5
  Locally advanced primary disease (n)           13/86 (15)
  Recurrent disease (n)                          73/86 (85)
   First recurrence                              59/73 (81)
   Multiple previous recurrences                 14/73 (19)
   Previous EBRT +/− BT                          59/73 (81)
   Previous surgery                              58/73 (79)
   Previous systemic therapy                     30/73 (41)
  Interval from diagnosis to recurrence (mo)           
   Median                                           25.0
   Range                                          3.1-379.4
  Tumor size in maximum dimension (cm)                 
   Median                                            5.0
   Range                                          0.5-14.0
  Tumor histology (n)                                  
   SCC                                             68 (79)
   AC                                              11 (13)
   ASC                                              6 (7)
   CC                                               1 (1)
  Tumor grade (n)                                      
   High                                            73 (85)
   Low                                              8 (9)
   Unknown                                          5 (6)

Abbreviations: EBRT = external beam radiotherapy; BT = brachytherapy; SCC = squamous cell carcinoma; AC = adenocarcinoma; ASC = adenosquamous carcinoma; CC = clear cell carcinoma.

In the 73 patients with recurrent disease, the median time from initial cancer diagnosis to recurrent treated with IOERT was 2.1 years (range, 0.3-31.6 years). Fourteen (19%) of those patients had previously experienced at least one previous local recurrence prior to IOERT. Therapy at the time of initial diagnosis in patients with recurrent disease consisted of primary surgery +/− chemotherapy (n = 23, 31%), primary EBRT and BT +/− chemotherapy (n = 18, 25%), or surgery and EBRT +/− chemotherapy (n = 32, 44%). In all, 59 patients (81%) with recurrent disease had previously received RT, 58 (79%) had previously undergone some form of surgery, and 30 (41%) had previously received systemic therapy. In the 13 patients with locally advanced primary disease, primary therapy consisted of surgery and EBRT in addition to IOERT, with 10 of 13 patients (77%) receiving adjuvant chemotherapy.

Treatment characteristics are summarized in Table [2](#T2){ref-type="table"}. The most common surgeries performed in conjunction with IOERT included pelvic exenteration (n = 26, 30%) and pelvic sidewall resection (n = 22, 26%), each occurring with or without lymph node dissection (LND). Other surgeries included paraaortic LND only (n = 17, 20%), exploration only (n = 12, 14%), radical hysterectomy/LND (n = 7, 8%), abdominal wall resection (n = 1, 1%), and inguinal LND (n = 1, 1%). In all, 58 patients (67%) were found to have tumor involving the pelvic sidewall. The most common surgical margin grade after maximal debulking was R0 (n = 35, 41%), but patients commonly had either microscopic (R1; n = 30, 35%) or gross (R2; n = 21, 24%) residual disease at the time of IOERT. The median IOERT dose was 15 Gy (range, 6.25-25 Gy), and the most commonly treated field was the hemipelvis (n = 53, 61%). The most common electron beam energy was 9 MeV (n = 44, 51%), and most patients (n = 74, 86%) were treated with a single IOERT field.

###### 

Treatment characteristics

  **Characteristic**                **Value (%)**
  -------------------------------- ---------------
  Surgery                                  
   Type of resection (n)                   
    Exenteration                       26 (30)
    Pelvic sidewall resection          22 (26)
    Paraaortic LND                     17 (20)
    Exploration                        12 (14)
    Radical hysterectomy/LND            7 (8)
    Abdominal wall resection            1 (1)
    Inguinal LND                        1 (1)
   Resection status (n)                    
    R0                                 35 (41)
    R1                                 30 (35)
    R2                                 21 (24)
  IOERT                                    
   IOERT dose (Gy)                         
    Median                               15
    Range                              6.25-25
   IOERT field (n)                         
    Hemipelvis                         53 (61)
    Paraaortic                         22 (26)
    Bilateral pelvis                    6 (7)
    Aortic bifurcation                  4 (5)
    Groin                               1 (1)
   IOERT energy (MeV)                      
    6                                   3 (4)
    9                                  44 (51)
    12                                 26 (30)
    15                                  5 (6)
    18                                  8 (9)
   IOERT cone size (cm)                    
   Median                                 7
   Range                                5-15
   Total IOERT fields (n)                  
    1                                  74 (86)
    2                                  11 (13)
    3                                   1 (1)
  Perioperative EBRT +/− BT                
   Timing (n)                              
    Pre-operative                      47 (55)
    Post-operative                     12 (14)
    Pre- and post-operative             2 (2)
    None                               25 (29)
   Dose (Gy)                               
    Median                               45
    Range                              19.8-83
  Perioperative chemotherapy (n)           
   Concurrent                          15 (17)
   Sequential                          26 (31)
   None                                45 (52)

Abbreviations: LND = lymph node dissection; IOERT = intraoperative electron beam radiotherapy; EBRT = external beam radiotherapy; BT = brachytherapy.

In addition to surgical debulking and IOERT, 61 patients (71%) received peri-operative EBRT +/− BT, including 35 patients with recurrent disease who had been previously irradiated. EBRT was most commonly administered preoperatively, though some patients were treated postoperatively or both pre- and postoperatively depending on surgical findings. BT techniques changed over the time interval in question from low-dose (LDR) to high-dose rate (HDR) implants. The median dose for all patients treated with perioperative RT was 45 Gy (range, 19.8-83 Gy). For patients with recurrent disease who had previously received RT, the median retreatment dose was 39.6 Gy (range, 20--54 Gy), although generally, any obviously overlapping fields were kept to a cumulative dose of ≤80 Gy. Some patients (n = 41, 48%) received perioperative chemotherapy in addition to surgery and IOERT. This was given concurrently with EBRT in 15 patients and sequentially in 26 patients. Systemic regimens varied over the study time interval but universally consisted of cisplatin-containing combination therapy.

Treatment outcomes
------------------

Median follow-up in living patients was 2.7 years (mean, 5.2 years; range, 0.1-25.5 years), and the median survival was 15 months. Cumulative incidences of CR, LRR and DR were 23, 38 and 43%, respectively, at 3 years (Figure [1](#F1){ref-type="fig"}A). Likewise, 3-year estimates of CSS and OS were 31 and 25% (Figure [1](#F1){ref-type="fig"}B). For patients with locally advanced primary disease, 3-year cumulative incidences of CR, LRR and DR were 22, 30 and 27%. For patients with recurrent cervical cancer, 3-year cumulative incidences of CR, LRR and DR were 23, 39 and 44%.

![Cumulative incidence of central relapse (CR), locoregional relapse (LRR), and distant relapse (DR; A) and cause-specific (CSS) and overall survival (OS; B).](1748-717X-8-80-1){#F1}

On univariate analysis, no factor was found to be prognostic for CR or LRR in patients with recurrent cervical cancer (Table [3](#T3){ref-type="table"}). Surgical margins were associated with DR (p = 0.004), with 3-year cumulative DR rates of 33, 44 and 51% for patients who underwent R0, R1, and R2 resections, respectively. This association was also true for CSS (p = 0.04), where 3-year estimates of CSS for R0, R1, and R2 resections were 45, 27, and 14%. The time interval from initial diagnosis to recurrence treated with IOERT was strongly associated with CSS (p = 0.001), and no patient recurring within 6 months of initial diagnosis survived 3 years. Risk factors for which no association could be established by Log-Rank testing included tumor grade, history of previous RT, history of multiple recurrences, time period during which IOERT occurred, size of tumor recurrence, type of surgery, tumor location, delivery of perioperative RT, and treatment with perioperative chemotherapy.

###### 

Univariate analysis of potential prognostic risk factors in patients treated with IOERT for recurrent cervical cancer

  **Variable**                         **3-year CC, %**   ***P***   **3-year LRC, %**   ***P***   **3-year FFDR, %**    ***P***    **3-year CSS, %**    ***P***
  ----------------------------------- ------------------ --------- ------------------- --------- -------------------- ----------- ------------------- -----------
  Tumor grade                                              0.68                          0.61                            0.46                            0.21
   Low                                        92                           50                             71                              59                
   High                                       65                           47                             42                              25                
  Previous RT                                              0.22                          0.61                           *0.08*                           0.28
   Yes                                        71                           54                             50                              33                
   No                                         66                           46                             37                              26                
  Multiple previous recurrences                            0.95                          0.20                            0.77                            0.72
   Yes                                        65                           45                             50                              32                
   No                                         71                           54                             47                              31                
  Time period of IOERT                                     0.16                          0.13                            0.63                            0.45
   1983-1996                                  60                           40                             45                              27                
   1997-2010                                  81                           68                             50                              39                
  Time from diagnosis to recurrence                        0.76                          0.47                            0.13                          **0.001**
   ≤6 months                                  80                           60                             25                               0                
   \>6 months                                 70                           52                             49                              34                
  Tumor size                                               0.67                          0.97                            0.46                            0.82
   \<3 cm                                     44                           35                             42                              22                
   ≥3 cm                                      74                           55                             48                              34                
  Type of surgery                                          0.13                          0.12                            0.60                            0.30
   Exenteration                               77                           58                             46                              41                
   Less extensive resection                   66                           49                             48                              27                
  Surgical margin grade                                    0.17                          0.13                          **0.004**                       **0.04**
   R0                                         82                           71                             61                              45                
   R1                                         55                           36                             45                              27                
   R2                                         81                           53                             25                              14                
  Pelvic sidewall involvement                              0.77                          0.76                            0.89                            0.37
   Yes                                        69                           50                             46                              28                
   No                                         70                           55                             48                              39                
  Perioperative RT                                         0.13                          0.11                            0.34                            0.29
   Yes                                        76                           60                             44                              36                
   No                                         52                           33                             60                              22                
  Perioperative systemic therapy                           0.35                          0.97                            0.44                            0.81
   Yes                                        74                           54                             53                              31                
   No                                         66                           51                             43                              32                

Abbreviations: CC = central control; LRR = locoregional control; FFDR = freedom from distant recurrence; CSS = cause-specific survival; RT = radiotherapy; IOERT = intraoperative electron beam radiotherapy.

Multivariate analysis revealed pelvic exenteration (p = 0.02) and perioperative RT (p = 0.009) to be associated with improved CC (Table [4](#T4){ref-type="table"}). The same was true for LRC, where both pelvic exenteration (p = 0.02) and perioperative RT (p = 0.01) predicted for improved LRC. Surgical margin grade was associated with FFDR, as both R0 (p = 0.004) and R1 (p = 0.02) resections predicted for improved FFDR compared to R2 resections; however, there was no association when R0 and R1 resections were directly compared. Factors associated with poor CSS included high tumor grade (p = 0.04) and recurrence within 6 months of initial diagnosis (p = 0.002). No other factor was statistically association with CSS, though trends for improved CSS were seen in patients who had an R0 (p = 0.07) or R1 (p = 0.08) resection compared to an R2 resection or who received perioperative RT (p = 0.07).

###### 

Multivariate analysis of potential prognostic risk factors in patients treated with IOERT for recurrent cervical cancer

  **Variable**                                  **CC**    **LRC**      **CSS**                                                    
  -------------------------------------------- -------- ------------ ----------- ------ ----------- ---------- ------ ----------- -----------
  High grade tumor                               0.92    0.17-3.97      0.91      0.78   0.24-2.14     0.64     0.40   0.14-0.96   **0.04**
  Recurrence ≤6 months after initial therapy     0.24    0.03-4.88      0.28      0.32   0.08-2.15     0.21     0.10   0.03-0.40   **0.002**
  Previous RT                                    2.21    0.57-9.00      0.25      1.26   0.43-3.51     0.66     1.40   0.60-3.20     0.43
  Pelvic exenteration                            4.18    1.15-20.62   **0.02**    3.01   1.19-8.55   **0.02**   1.75   0.83-3.90     0.15
  Surgical margin grade                                                                                                                 
   R0 vs. R2                                     0.69    0.13-3.52      0.65      1.60   0.56-4.61     0.38     2.25   0.94-5.42    *0.07*
   R1 vs. R2                                     0.54    0.12-1.90      0.35      1.20   0.47-2.89     0.69     2.02   0.92-4.34    *0.08*
   R0 vs. R1                                     1.29    0.34-5.61      0.72      1.33   0.51-3.64     0.56     1.11   0.50-2.50     0.79
  Perioperative RT                               5.54    1.52-23.86   **0.009**   3.38   1.30-9.19   **0.01**   2.09   0.93-4.67    *0.07*
  Perioperative systemic therapy                 0.98    0.33-3.10      0.97      0.74   0.33-1.63     0.45     0.86   0.44-1.69     0.66

Toxicity
--------

Toxicity graded as being potentially related to delivery of IOERT (effects that may not have occurred if IOERT had been excluded from treatment) was reported by 30 patients (35%). The most serious was a bowel perforation that led to a patient's death. Other serious side effects included one grade 4 bowel perforation as well as cases of ureteral stenosis (n = 4), abscess formation (n = 2), fistula formation (n = 2), peripheral neuropathy (n = 1), hemorrhage (n = 1), and severe soft tissue fibrosis (n = 1), each grade 3. In all, 16 patients (19%) experienced some degree of peripheral neuropathy, and 11 of these (13%) required some form of long-term prescription pain medication.

Discussion
==========

In this study, we report the outcomes of patients with cervical carcinoma treated with IOERT. We found that long-term survival is possible with combined modality therapy including IOERT for advanced cervical cancer, even in women with poor prognostic factors, such as pelvic sidewall disease or large tumor size. While distant relapse after salvage therapy was a common pattern in this population, a significant number of patients still experienced local recurrence in spite of aggressive treatment. This finding underscores the challenging nature of treating advanced cervical cancer.

Treatment for recurrent cervical cancer is usually a function of initial cancer therapy, site of recurrence, and patient performance status and comorbidity. In patients treated with primary RT who experience a vaginal apex or paravaginal tissue recurrence without pelvic sidewall involvement, salvage rates with radical hysterectomy approach 40% in appropriately-selected patients \[[@B26],[@B27]\]. Patients treated with primary surgery who experience a vaginal cuff recurrence have a similar salvage rate when treated with concurrent RT and cisplatin-based chemotherapy \[[@B6],[@B28]\]. Pelvic exenteration is typically reserved for more extensive pelvic recurrences involving the bladder, lower vagina, and/or rectum and can result in long-term survival in a small percentage of patients \[[@B29]-[@B32]\]. When tumor involves the pelvic sidewall, as is the case in the majority of patients in this study, salvage outcomes are universally poor, and resection of these recurrences is generally considered to be futile \[[@B6],[@B7]\]. In the 58 patients with pelvic sidewall involvement treated with IOERT in this study, 3-year rates of CC, LRC, and CSS were 69, 50, and 25%, respectively, indicating that a small but quantifiable number of patients with pelvic sidewall involvement can be salvaged with a combined modality approach that includes IOERT.

Previously reported factors prognostic for improved clinical outcomes in patients with recurrent cervical cancer include: disease-free interval \>6 months, recurrent tumor \<3 cm in size, and no pelvic sidewall fixation \[[@B10]\]. On univariate analysis, we found that disease-free interval \>6 months was associated with improved CSS (p = 0.001), but neither tumor size nor pelvic sidewall involvement were predictive of clinical outcomes. Interestingly, surgical margin grade (R0 vs. R1 vs. R2) was prognostic for FFDR (p = 0.004) and CSS (p = 0.04) but did not appear to influence CC or LRC. This finding was confirmed on the multivariate analysis, where both R0 (p = 0.004) and R1 (p = 0.02) resections were associated with improved FFDR, but no correlation was found between surgical margin status and local disease control. The finding that surgical margin status is predictive of distant rather than local progression has been previously reported by our group \[[@B15]\] and could be due to a number of factors. Firstly, an R2 resection may be indicative of more extensive local disease which could in turn predict for a higher likelihood of occult distant spread, and these patients may succumb to distant metastasis before local recurrence is detected. It is also possible that cutting through tumor during an R2 resection may result in dissemination of tumor cells throughout the abdominal cavity, promoting distant recurrence. Indeed, some groups have reported a rare but quantifiable incidence of cervical cancer port site recurrences after laparoscopic surgery, implying peritoneal spread is possible with this malignancy \[[@B33]\]. Finally, cervical squamous cell carcinoma (SCC) may be more radiosensitive than other pelvic malignancies \[[@B34]\], which could result in patients with SCC benefitting more from IORT than those with other tumors. Thus, the impact of surgical margin status on disease control within the IORT field would be minimal, but IORT would have no effect on systemic disease control. This last scenario makes the strongest argument for including IORT as a component of treatment for locally advanced or recurrent SCC of the cervix.

Table [5](#T5){ref-type="table"} summarizes the published literature on IORT for cervical cancer \[[@B14],[@B16]-[@B24]\]. Clinical outcomes from the current series, including crude rate of locoregional relapse, median survival, and OS compare favorably with those reported from other groups. Our study represents the largest of its kind, both for total number of patients and number of patients with recurrent cervical cancer treated with IORT. Three other large series of note include two French studies, one of which is a single-institution experience (n = 54) \[[@B17]\] and the other a multi-institutional effort (n = 70) \[[@B19]\], and one other from Spain (n = 66) \[[@B20]\]. Outcomes in patients with recurrent disease in the single-institutional French study and the Spanish study were similar to those in the current study, but the French multi-institutional group reported significantly worse survival (8% at 3 years) \[[@B19]\]. Potential reasons for this may be that only 43% of patients in that study received EBRT in addition to IORT, only 43% of patients underwent an R0/R1 resection, and/or patients were treated at one of several institutions where the IORT procedure may not have been common practice. Aside from the current study, the most recent series comes from Stanford University \[[@B22]\], and includes 17 patients with cervical cancer among 36 total patients with recurrent gynecologic malignancies. They report excellent outcomes in women with recurrent cervical cancer at 5 years, with 45% LRC and 46% CSS. One potential reason for these seemingly superior outcomes at 5 years is that only 32% of the patients from the Stanford series had pelvic sidewall involvement, compared to 67% in the current series. Additionally, 18% of the patients in the Stanford series underwent exenteration, while 30% had an exenteration in our study, implying a more advanced disease state in the patients treated at our institution. Another interesting difference between these studies is that the Stanford data showed no benefit to exenteration compared to less extensive surgery, while in our series, exenteration predicted for improved CC and LRC. The reason for this difference is unclear but may in part be due to sampling error, as only 7 patients underwent exenteration in the Stanford series. Overall, the median survival after IORT in the studies summarized in Table [5](#T5){ref-type="table"} ranged from 7--27 months, and OS ranged from 8-54% at 3 years.

###### 

Literature review of IORT for cervical cancer

  **Series**                          **Date**   **Patients (n)**   **Advanced primary or recurrent**   **IORT modality**   **Median IORT dose (Gy)**   **Crude LRR**   **Median survival (mos)**         **OS**
  ---------------------------------- ---------- ------------------ ----------------------------------- ------------------- --------------------------- --------------- --------------------------- --------------------
  Hicks et al \[[@B18]\].               1993            13                      Recurrent                 Orthovoltage                 15                   7/13                    7                       \-
  Konski et al \[[@B24]\].              1993            8                        Primary                      IOERT                    20                    7/8                   27                       \-
                                                        5                       Recurrent                     IOERT                    20                    \-                     9                       \-
  Gerard et al \[[@B17]\].              1994            20                       Primary                      IOERT                    \-                   4/20                   \-                 75% at 18 mos
                                                        34                      Recurrent                     IOERT                    \-                   6/34                   \-                  32% at 4 yrs
  Stelzer et al \[[@B23]\].             1995            22                      Recurrent                     IOERT                    22                   10/22                  26               43% at 5 yrs (CSS)
  Mahé et al \[[@B19]\].                1996            70                      Recurrent                     IOERT                    19                   50/67                  11                  8% at 3 yrs
  del Carmen et al \[[@B14]\].          2000            5                       Recurrent                     IOERT                    15                    2/5                   \-                       \-
  Gemignani et al \[[@B16]\].           2001            9                       Recurrent                    HDR-BT                    14                    \-                    \-                  54% at 3 yrs
  Martinez-Monge et al \[[@B20]\].      2001            31                       Primary                      IOERT                    12                   6/31                   \-                 58% at 10 yrs
                                                        36                      Recurrent                     IOERT                    15                   18/36                  \-                 14% at 10 yrs
  Roth et al \[[@B21]\].                2003            1                       Recurrent                    HDR-BT                    15                    0/1                   20                       \-
  Tran et al \[[@B22]\].                2007            17                      Recurrent                 Orthovoltage                11.5                   \-                    \-               47% at 5 yrs (CSS)
  **Current series**                  **2012**        **13**                   **Primary**                  **IOERT**               **12.5**              **4/13**               **13**              **29% at 3 yrs**
                                                      **73**                  **Recurrent**                 **IOERT**               **17.5**              **33/73**              **17**              **25% at 3 yrs**

Abbreviations: IORT = intraoperative radiotherapy; LRR = locoregional recurrence; OS = overall survival; IOERT = intraoperative electron beam radiotherapy; CSS = cause-specific survival; HDR-BT = high-dose rate brachytherapy.

Conclusions
===========

While the current study is retrospective in nature and subject to the usual elements of bias and uncertainty, it provides evidence to support the concept that a small but significant proportion of women with locally advanced or recurrent cervical cancer may experience long-term survival after combined modality therapy including IOERT. Because treatment-related morbidity with this approach can be severe, it must be balanced against both the likelihood of cure and the risk of morbidity from untreated local disease. Good candidates for combined modality therapy with IOERT include women with a disease-free interval \>6 months who will tolerate pelvic exenteration if necessary. If possible, perioperative RT with concurrent chemotherapy should be strongly considered, even in previously irradiated patients, as the delivery of perioperative RT was associated with improved LRC. Patients who do not meet these criteria should be considered for a less aggressive approach that may involve palliative RT and/or surgery, along with palliative chemotherapy.
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